{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-26-000013","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2026-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.416581+00:00","generated_at":"2026-05-15T22:57:38.718936+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ANI Pharma reports record Q4 revenue $247M, EPS $1.18; reaffirms 2026 guidance","bullets":["Q4 total net revenue $247.1M (+29.6% YoY); Rare Disease segment $131.3M (+50.8%), Cortrophin Gel $111.4M (+87.6%).","Q4 GAAP diluted EPS $1.18; adjusted diluted EPS $2.33. Full year revenue $883.4M (+43.8%).","Generics Q4 revenue $100.8M (+28.2%) driven by partnered launch and new products.","Reaffirms FY2026 guidance: total revenue $1.055-1.115B; Cortrophin Gel $540-575M; adjusted EBITDA $275-290M.","Cash and equivalents $285.6M; operating cash flow $185.2M in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-26-000013","json":"https://secwatch.observer/filing/0001023024-26-000013.json","markdown":"https://secwatch.observer/filing/0001023024-26-000013.md","text":"https://secwatch.observer/filing/0001023024-26-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302426000013/0001023024-26-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302426000013/ani-20260227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:57:38.718936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}